Peer-Reviewed Publication
NPJ Breast Cancer2026June 12, 2026Journal Article
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.
S A Wander1, C M Weipert2, L Cabel3, J Liao2, N Zhang2, A Safonov3,4, A Bardia5, P Razavi6,7
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. swander@mgh.harvard.edu.
2Guardant Health, Inc., Palo Alto, CA, USA.
3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4Weill Cornell Medicine, New York, NY, USA.
5UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org.
7Weill Cornell Medicine, New York, NY, USA. razavip@mskcc.org.
Abstract
A large clinical-genomic database was used to assess circulating tumor DNA (ctDNA) pre- and post-CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment in a cohort of patients with HR+/HER2- metastatic breast cancer (mBC). A panel of putative resistance alterations to CDK4/6i + ET (CDK4/6i+ET-R) was developed based upon previous studies. Patients with ≥1 baseline CDK4/6i + ET-R were comp…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans